1. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?

2. Expert Panelists

3. Program Goals

4. Evaluating CV Risk in New Antidiabetic Therapies

5. FDA Guidance

9. EXAMINE and SAVOR-TIMI 53

11. EXAMINE New Analyses

12. SAVOR-TIMI 53 Saxagliptin in Patients With T2D and History of/at Risk for CV Events

13. Advisory Committee

14. SAVOR-TIMI 53 Hospitalization for Heart Failure

15. TECOS

16. TECOS Sitagliptin in Patients With T2D and Established CVD

17. TECOS CV Outcomes

18. TECOS Non-CV Outcomes

19. TECOS, EXAMINE, and SAVOR-TIMI 53 Patient Population

20. TECOS, EXAMINE, and SAVOR-TIMI 53 Hospitalization for Heart Failure

21. SGLT2 Inhibitors and Renal Effects

22. SGLT2 Inhibitors Renal Effects

23. SGLT2 Inhibitors Blood Pressure Effects

24. SGLT2 Inhibitors and Antihypertensive Action Proposed MOA

25. SGLT2 Inhibitors and Natriuretic Effect RCT of Dapagliflozin vs HCTZ vs Placebo

26. CREDENCE Evaluation of Canagliflozin on Renal and CV Outcomes in Participants With Diabetic Nephropathy

27. SGLT2 Inhibitor + DPP-4 Inhibitor FDC

28. Empagliflozin + Linagliptin FDC Effect on HbA1c

29. Empagliflozin + Linagliptin FDC Effect on Body Weight

30. TECOS Sitagliptin in Patients With T2D and Established CVD

31. Empagliflozin + Linagliptin FDC Effect on HbA1c Is Not Additive

32. SGLT2 + DPP4 FDC Potential Advantages/Disadvantages

33. Abbreviations

34. References

35. References (cont)

36. References (cont)

37. References (cont)

38. References (cont)

39. References (cont)